Medications to Manage Nausea on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond

What the label reports at 0.5, 1 and 2 mg

In pooled placebo-controlled trials in type 2 diabetes (262 placebo, 260 on 0.5 mg, 261 on 1 mg; mean 32.9 weeks), nausea occurred in 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg; vomiting in 2.3%, 5% and 9.2%; any GI reaction in 15.3%, 32.7% and 36.4%; and treatment was stopped for GI reasons in 0.4%, 3.1% and 3.8% [1].

In a 40-week trial of 959 patients on metformin with or without a sulfonylurea, GI reactions occurred in 34% on 2 mg versus 30.8% on 1 mg, with no new safety signals; that summary gives no separate 2 mg nausea rate [1].

Most reports of nausea, vomiting and diarrhea occurred during dose escalation [1]. Ozempic starts at 0.25 mg weekly for 4 weeks (not a maintenance dose) before increasing to 0.5 mg, and later steps follow at least 4 weeks at the current dose [1].

When nausea is a warning sign

Severe GI reactions occurred in 0.4% on 0.5 mg and 0.8% on 1 mg versus 0% on placebo, and Ozempic is not recommended in patients with severe gastroparesis [1]. Postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1].

The pancreatitis warning describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting; if pancreatitis is suspected, the label says to discontinue Ozempic and begin appropriate management [1]. The label's kidney warning describes acute kidney injury reported mostly in patients whose GI reactions led to dehydration, and says renal function should be monitored in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].